Cutler Group’s Soleno Therapeutics SLNO Stock Holding History

Cutler Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$3K	Buy	+3,400	New	+$154K	﹤0.01%	1755
2020 Q3	–	Sell	-11,007	Closed	-$5K	–	5218
2020 Q2	$5K	Buy	+11,007	New	+$477K	﹤0.01%	3339

Other funds holding SLNO

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's SLNO Position: Q3 2022 in Review

Cutler Group sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 73 shares.

Cutler Group first reported a position in SLNO in Q2 2020 and held it in 9 quarters. The position peaked at $2K in Q4 2020. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

Cutler Group reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 73 Soleno Therapeutics shares in Q3 2022.
Cutler Group first reported a position in Soleno Therapeutics in Q2 2020 and held it in 9 quarters.
Cutler Group's Soleno Therapeutics position peaked at $2K in Q4 2020.
22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.